Dyadic International (DYAI) vs Scilex (SCLX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Dyadic International (DYAI) has outperformed Scilex (SCLX) over the past year, losing 60.7% versus a loss of 73.0%. Over five years, DYAI leads with a -90.8% price change compared with -98.6% for SCLX. Scilex is the larger company by market cap ($20.8 million vs $17.8 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DYAI | SCLX |
|---|---|---|
| Share price | $0.4444 | $2.96 |
| Market cap | $17.80M | $20.82M |
| 1-day change | -2.65% | -15.19% |
| YTD return | -52.72% | -61.03% |
| 1-year return | -60.67% | -72.96% |
| 5-year return | -90.84% | -98.65% |
| Forward P/E | — | 4.05 |
| EPS (TTM) | $-0.23 | $-49.70 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.60 | $16.81 |
| 52-week low | $0.34 | $2.62 |
| Distance from 52-week high | -72.23% | -82.39% |
| Average volume | 202.50K | 53.62K |
| Shares outstanding | 40.06M | 7.03M |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DYAI has outperformed SCLX by 12.3 percentage points over the past year.
DYAI vs SCLX FAQ
Which is bigger, Dyadic International or Scilex?
Scilex (SCLX) is larger, with a market capitalization of $20.82M compared with $17.80M for Dyadic International (DYAI).
Which stock has performed better over the past year, DYAI or SCLX?
DYAI returned -60.67% over the past 12 months, compared with -72.96% for SCLX (price return, excluding dividends). Past performance does not predict future results.
Are Dyadic International and Scilex in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.